MSB 3.21% $1.13 mesoblast limited

Well this was a bit of a surprise, but considering the market...

  1. 2,126 Posts.
    lightbulb Created with Sketch. 1777
    Well this was a bit of a surprise, but considering the market outside of C-19 ARDS, there’s a larger prize in the horizon!

    Also, @Duku I wouldn’t call CHF a fail because of the 60% reduction in mortality that is really, a key secondary endpoint.

    That sort of data from the trial is very compelling!

    Ive not sold anything yet, in it for the long run!
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.